| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a135a933620c99beab01d4ac785d25 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45 |
| filingDate |
2007-01-19^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-10-25^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe5fd60f5e75a1e9f7951bbdcdf87c1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70bd993e7962ae6a588f290119ee3829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13318a96f016295fd2233049c7f2a686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30230a7e7e941072c559b238febab40f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16f6fde79ee50c4b93d2417eea1bc5c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0f136498bec6b2249119c773094bf2a |
| publicationDate |
2016-10-25^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2574531-C |
| titleOfInvention |
Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| abstract |
The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells, e.g. tumor cells, to enhance their destruction by cytotoxic lymphocytes. |
| priorityDate |
2007-01-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |